Tỷ lệ tử vong do ung thư tuyến tụy là bao nhiêu?

Mỗi con số dưới đây là những gì mỗi nguồn đã báo cáo, cùng với trích dẫn nguyên văn mà chúng tôi dựa vào và cách chúng tôi đưa ra con số của mình. Nhấp vào bất kỳ liên kết nào để xác minh trực tiếp.

1/5 nguồn được xác minh độc lập đúng từng chữ so với nguồn được trích dẫn

1. [1] International Agency for Research on Cancer (IARC) / World Health Organization — Pancreatic Cancer Báo cáo chính phủ

   Pancreatic Cancer

   Thống kê

   More than 500,000 pancreatic cancer cases diagnosed in 2022 and almost 470,000 deaths globally; 12th most common cancer but 6th most common cause of cancer death; one of the cancer types with the least favourable prognosis

   Trích đoạn

   “"more than 500 000 people estimated to have been diagnosed with pancreatic cancer in 2022 [...] almost 470 000 deaths in 2022 [...] only the 12th most common cancer type globally [...] the sixth most common cause of cancer death [...] It is one of the cancer types with the least favourable prognosis." ”

   Dữ liệu nguồn từ

   2024-04-04

   Truy cập

   2026-04-11 · bản sao lưu trữ

   Tính toán

   GLOBOCAN 2022 headline used directly as the native number. ~467,000 annual global pancreatic cancer deaths across ~5.5 billion adults is ~0.85 per 10,000 adult-years. Age-weighted over a 60-year adult window — pancreatic cancer hazard in the 60s and 70s is several times the adult average — gives a lifetime adult-lifetime mortality near 0.008 (~1 in 125). The ranking mismatch (12th in incidence, 6th in mortality) is the core quantitative statement of the "diagnosis ≈ death" story and is used directly in the long-form body text.

   Độc lập

   IARC GLOBOCAN is the upstream dataset used by WHO, ACS international comparisons, and the IHME Global Burden of Disease pancreatic cancer module. Treat this as the canonical global source; the SEER and ACS US numbers below are methodologically independent cross-checks.

2. [2] Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute — Cancer Stat Facts: Pancreatic Cancer Báo cáo chính phủ

   Cancer Stat Facts: Pancreatic Cancer

   Thống kê

   5-year relative survival 13.3% (2015-2021); ~1.6% of men and women will be diagnosed with pancreatic cancer at some point during their lifetime; estimated 67,440 new cases and 51,980 deaths in 2025; 3.3% of all new cancer cases; stage distribution at diagnosis is 15% localized, 28% regional, 51% distant, 5% unknown

   Trích đoạn

   “"5-Year Relative Survival: 13.3% [...] Approximately 1.6 percent of men and women will be diagnosed with pancreatic cancer at some point during their lifetime [...] Estimated New Cases in 2025: 67,440 [...] Estimated Deaths in 2025: 51,980 [...] 3.3% of all new cancer cases. [...] For pancreatic cancer, 15.4% are diagnosed at the local stage. [...] Stage Distribution (%): Localized 15 [...] Regional 28 [...] Distant 51 [...] Unknown 5." ”

   Dữ liệu nguồn từ

   2025-04-01

   Truy cập

   2026-04-11 · bản sao lưu trữ

   Tính toán

   SEER gives direct lifetime incidence of ~1.6% for the US population. With 5-year relative survival at 13.3% — the lowest of any common solid tumor — the implied long-run case-fatality is roughly 85-90%. 1.6% lifetime incidence × ~88% long-run case-fatality yields a US lifetime pancreatic-cancer-death probability of ~1.4% (~1 in 71), consistent with the ACS lifetime-risk page. The ratio of annual deaths (~52,000) to annual new cases (~67,000) is ~0.78 on a single-year basis, which understates the long-run case-fatality because most deaths occur outside the diagnosis year. This anchors the US row in the regional breakdown and the top of the Likelier uncertainty band. The same SEER page's stage-distribution table shows 51% of cases are diagnosed at the distant (metastatic) stage versus only 15% localized — the direct source for the body text's "roughly half of cases present" at the distant stage, and the diagnosis-time complement to the stage-conditional survival figures in the ACS survival-rates source below.

   Độc lập

   SEER (NCI) and IARC GLOBOCAN (WHO) are methodologically independent compilation pipelines. SEER uses US vital registration and population-based cancer registries; IARC aggregates national registry data worldwide.

3. [3] American Cancer Society — Key Statistics for Pancreatic Cancer Nguồn tham khảo

   Key Statistics for Pancreatic Cancer

   Thống kê

   Lifetime risk of pancreatic cancer ~1 in 56 in men and ~1 in 60 in women; ~67,530 new cases and ~52,740 deaths projected for 2026 in the US; ~3% of US cancers but ~8% of US cancer deaths

   Trích đoạn

   “"The average lifetime risk of pancreatic cancer is about 1 in 56 in men and about 1 in 60 in women. [...] About 67,530 people (35,190 men and 32,340 women) will be diagnosed with pancreatic cancer. [...] About 52,740 people (27,230 men and 25,510 women) will die of pancreatic cancer." ”

   Dữ liệu nguồn từ

   2026-01-16

   Truy cập

   2026-04-11 · bản sao lưu trữ

   Tính toán

   ACS projects ~67,530 US new cases and ~52,740 US deaths in 2026 — a ratio of ~0.78 annual deaths to annual diagnoses, which is the single most compressed deaths-to-cases ratio of any common US cancer. The "about 3% of all cancers but about 8% of all cancer deaths" framing is used in the body text as the plain-English version of the GLOBOCAN "12th in incidence, 6th in mortality" ranking. The lifetime-risk-of- developing figures (~1 in 56 men, ~1 in 60 women) combined with the ~85-90% long-run case-fatality from SEER give the ~1.4% US lifetime pancreatic-cancer-death probability used as the US anchor.

   Độc lập

   ACS Key Statistics and SEER Stat Facts share the same US vital registration and cancer registry upstream. Treat as a single institutional pipeline for the US-specific figures; the IARC source is the methodologically independent global cross-check.

4. [4] American Cancer Society — Survival Rates for Pancreatic Cancer Nguồn tham khảo

   Survival Rates for Pancreatic Cancer

   Thống kê

   5-year relative survival by stage (SEER 2015-2021): localized 44%, regional 17%, distant 3%, all stages combined 13%

   Trích đoạn

   “"Localized 44% [...] Regional 17% [...] Distant 3% [...] All SEER stages combined 13%." ”

   Dữ liệu nguồn từ

   2025-03-14

   Truy cập

   2026-04-11 · bản sao lưu trữ

   Tính toán

   Stage-conditional 5-year survival figures used in the long-form body text. The gap between localized (44%) and distant (3%) is roughly 15x, the largest stage-conditional survival gap of any common cancer in the SEER system. Combined with the fact that only about 12-15% of pancreatic cancers are diagnosed at the localized stage (per SEER staging distribution), the "no effective screening" story falls out arithmetically: the tumor is almost always metastatic or locally advanced at diagnosis.

   Độc lập

   Draws on the same SEER staging distribution and relative survival pipeline as the SEER Stat Facts source above. Used as the stage- conditional cross-reference, not as an independent verification of the aggregate mortality figure.

5. [5] Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM / Cancer Research — Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States Đã xác minh Được bình duyệt

   Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States

   Thống kê

   Pancreas and liver cancers are projected to surpass breast, prostate, and colorectal cancers to become the second and third leading causes of cancer-related death in the US by 2030

   Trích đoạn

   “"pancreas and liver cancers are projected to surpass breast, prostate, and colorectal cancers to become the second and third leading causes of cancer-related death by 2030." ”

   Dữ liệu nguồn từ

   2014-06-01

   Truy cập

   2026-04-11 · bản sao lưu trữ

   Xác minh

   Trích đoạn đã được tải lại độc lập và xác nhận đúng từng chữ so với nguồn được trích dẫn trong quá trình kiểm định căn cứ của chúng tôi.

   Tính toán

   Rahib et al. 2014 is the widely cited source for the "second leading cause of US cancer death by 2030" projection used in the body text. The projected rise in ranking is driven almost entirely by improvements in treating the currently-larger cancers (breast, prostate, colorectal) and by population ageing, not by deteriorating pancreatic outcomes — age-standardized pancreatic cancer mortality has been roughly flat for decades. Used as the "trend" paragraph anchor, not as part of the headline probability calculation.

   Độc lập

   Rahib et al. projects from SEER incidence and NCHS mortality data, so upstream is the same as the SEER/ACS sources. Independent analytically in the sense that it is a projection model rather than a retrospective count, but not an independent data pipeline.